Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

被引：2

作者：

Timmerman, John ^{[1
]}

Lavie, David ^{[2
]}

Johnson, Nathalie A. ^{[3
]}

Avigdor, Abraham ^{[4
]}

Borchmann, Peter ^{[5
]}

Andreadis, Charalambos ^{[6
]}

Bazargan, Ali ^{[7
,8
]}

Gregory, Gareth P. ^{[9
]}

Keane, Colm ^{[10
]}

Tzoran, Inna ^{[11
]}

Vucinic, Vladan ^{[12
]}

Zinzani, Pier Luigi ^{[13
,14
]}

West, Rachel Marceau ^{[15
]}

Pillai, Pallavi ^{[15
]}

Marinello, Patricia ^{[15
]}

Herrera, Alex F. ^{[16
]}

机构：

[1] UCLA, Med Ctr, Los Angeles, CA USA

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada

[4] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[5] Univ Hosp Cologne, Cologne, Germany

[6] UCSF, San Francisco, CA USA

[7] Univ Melbourne, Melbourne, Vic, Australia

[8] St Vincents Hosp, Fitzroy, Vic, Australia

[9] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Australia

[10] Princess Alexandra Hosp, Brisbane, Qld, Australia

[11] Rambam Hlth Care Campus, Haifa, Israel

[12] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Cell Therapy & Hemostaseo, Leipzig, Germany

[13] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[14] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[15] Merck & Co Inc, Rahway, NJ USA

[16] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[11] Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Carlo-Stella, Carmelo
Ansell, Stephen
Zinzani, Pier Luigi
Radford, John
Maddocks, Kami
Pinto, Antonio
Collins, Graham P.
Bachanova, Veronika
Bartlett, Nancy
Bence-Bruckler, Isabelle
Hamadani, Mehdi
Kline, Justin
Mayer, Jiri
Savage, Kerry J.
Advani, Ranjana
Caimi, Paolo
Casasnovas, Rene-Olivier
Feldman, Tatyana
Hess, Brian
Bastos-Oreiro, Mariana
Iyengar, Sunil
Eisen, Sandy
Negievich, Yanina
Wang, Luqiang
Wuerthner, Jens
Herrera, Alex F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S347 - S347
[12] A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
Carlo-Stella, Carmelo
Zinzani, Pier Luigi Luigi
Sureda, Anna
Araujo, Luis Francisco
Casasnovas, Olivier
Carpio, Cecilia
Yeh, Su-Peng
Bouabdallah, Krimo
Cartron, Guillaume
Kim, Won Seog
Cordoba, Raul
Koh, Youngil
Re, Alessandro
Alves, Daniela
Chamuleau, Martine E. D.
Le Gouill, Steven
Lopez-Guillermo, Armando
Moreira, Maria Ilidia
Van Der Poel, Marjolein W. M.
Abbadessa, Giovanni
Meng, Robin
Ji, Ran
Lepine, Lucie
Saleem, Rao
Ribrag, Vincent
BLOOD, 2021, 138
[13] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
Carlo-Stella, Carmelo
Zinzani, Pier Luigi
Sureda, Anna
Araujo, Luis
Casasnovas, Olivier
Carpio, Cecilia
Yeh, Su-Peng
Bouabdallah, Krimo
Cartron, Guillaume
Kim, Won Seog
Cordoba, Raul
Koh, Youngil
Re, Alessandro
Alves, Daniela
Chamuleau, Martine
Le Gouill, Steven
Lopez-Guillermo, Armando
Moreira, Ilidia
van der Poel, Marjolein W. M.
Abbadessa, Giovanni
Meng, Robin
Ji, Ran
Lepine, Lucie
Saleem, Rao
Ribrag, Vincent
HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
[14] Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Diefenbach, Catherine S.
Hong, Fangxin
Ambinder, Richard F.
Cohen, Jonathan B.
Robertson, Michael J.
David, Kevin A.
Advani, Ranjana H.
Fenske, Timothy S.
Barta, Stefan K.
Palmisiano, Neil D.
Svoboda, Jakob
Morgan, David S.
Karmali, Reem
Sharon, Elad
Streicher, Howard
Kahl, Brad S.
Ansell, Stephen M.
LANCET HAEMATOLOGY, 2020, 7 (09): : E660 - E670
[15] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Graham, Anne
Ramchandren, Radhakrishnan
BLOOD, 2011, 118 (21) : 1169 - 1169
[16] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Chau, Quincy
Ramchandren, Radhakrishnan
BLOOD, 2012, 120 (21)
[17] Glofitamab Monotherapy In Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Updated Analysis From A Phase 1/2 Study
Phillips, Tycel
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Crump, Michael
Trneny, Marek
Bartlett, Nancy L.
Zaucha, Jan
Wrobel, Tomasz
Offner, Fritz
de L'Etang, Audrey Filezac
Relf, James
Carlile, David J.
Byrne, Ben
Mulvihill, Estefania
Lundberg, Linda
Dickinson, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S516
[18] A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma
Rueda, Antonio
Garcia-Sanz, Ramon
Pastor, Miguel
Salar, Antonio
Labrador, Jorge
Quero-Blanco, Cristina
Casanova, Maria
Provencio, Mariano
ACTA ONCOLOGICA, 2015, 54 (06) : 933 - 938
[19] A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Bartlett, Nancy L.
Herrera, Alex F.
Domingo-Domenech, Eva
Mehta, Amitkumar
Forero-Torres, Andres
Garcia-Sanz, Ramon
Armand, Philippe
Devata, Sumana
Izquierdo, Antonia Rodriguez
Lossos, Izidore S.
Reeder, Craig
Sher, Taimur
Chen, Robert
Schwarz, Sylvia E.
Alland, Leila
Strassz, Andras
Prier, Kim
Choe-Juliak, Cassandra
Ansell, Stephen M.
BLOOD, 2020, 136 (21) : 2401 - 2409
[20] The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients - A prospective, open-label, controlled, randomized study
Jensen-Fangel, S
Thomsen, HF
Larsen, L
Black, FT
Obel, N
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 27 (02) : 124 - 129

← 1 2 3 4 5 →